Cost Management Insights: SG&A Expenses for AstraZeneca PLC and argenx SE

Cost Management Insights: SG&A Expenses for AstraZeneca PLC and argenx SE

In the ever-evolving pharmaceutical industry, effective cost management is crucial for maintaining competitive advantage. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: AstraZeneca PLC and argenx SE, from 2014 to 2023.

AstraZeneca PLC: A Decade of Strategic Spending

AstraZeneca's SG&A expenses have shown a steady increase, peaking in 2022 with a 42% rise from 2016. This trend reflects the company's strategic investments in marketing and administrative capabilities to support its expanding portfolio.

argenx SE: Rapid Growth and Scaling

In contrast, argenx SE's SG&A expenses have skyrocketed, increasing by over 16,600% from 2014 to 2023. This surge underscores argenx's rapid growth and scaling efforts as it transitions from a biotech startup to a major industry player.

These insights highlight the diverse strategies employed by pharmaceutical companies in managing operational costs while pursuing growth and innovation.